Market Overview - As of June 10, the Shanghai Composite Index closed at 3384.82 points, down 14.96 points, a decrease of 0.44% [1] - The Shenzhen Component Index closed at 10162.18 points, down 87.96 points, a decrease of 0.86% [1] - The ChiNext Index closed at 2037.27 points, down 24.02 points, a decrease of 1.17% [1] High Turnover Stocks - A total of 145 A-shares had a turnover rate exceeding 20% on June 10, with six stocks, including Kangliyuan and Jiaoda Tefa, having turnover rates above 50% [1] - The stock with the highest turnover rate was Kangliyuan (301287) at 78.20%, closing at 55.00 yuan with a price increase of 13.17% [1] - Jiaoda Tefa (920027) had a turnover rate of 72.03%, closing at 31.90 yuan with a significant price increase of 262.09% [1] Notable Stocks - Zhongke Magnetic (301141) had a turnover rate of 59.04%, closing at 55.02 yuan with a price increase of 20.00% [1] - Guokang Biochemical (300804) had a turnover rate of 56.79%, closing at 50.85 yuan with a price decrease of 10.32% [1] - Hai Chen Pharmaceutical (300584) had a turnover rate of 51.03%, closing at 42.27 yuan with a price increase of 2.95% [1] Additional High Turnover Stocks - Yuyin Co. (002177) had a turnover rate of 50.51%, closing at 7.73 yuan with a price decrease of 5.96% [1] - Zhongdian Xindong (002298) had a turnover rate of 49.62%, closing at 8.45 yuan with a price increase of 10.03% [1] - Huamai Technology (603042) had a turnover rate of 49.46%, closing at 18.37 yuan with a price decrease of 5.79% [1]

Group 1 - The assisted reproductive concept sector increased by 3.33%, ranking 10th among concept sectors, with 68 stocks rising, including Haichen Pharmaceutical which hit a 20% limit up, and others like Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical also reaching their limit up [1][2] - Notable gainers in the assisted reproductive sector included Xinghao Pharmaceutical, Shengnuo Biological, and Saiseng Pharmaceutical, which rose by 27.29%, 17.58%, and 6.08% respectively [1][6] - The sector saw a net inflow of 414 million yuan from main funds, with 31 stocks receiving net inflows, and 6 stocks exceeding 30 million yuan in net inflow, led by Zhongsheng Pharmaceutical with a net inflow of 247 million yuan [2][3] Group 2 - The top three stocks by net inflow ratio in the assisted reproductive sector were Zhongsheng Pharmaceutical at 55.08%, Shuanglu Pharmaceutical at 20.11%, and Meinuo Pharmaceutical at 17.33% [3][4] - The trading volume and turnover rates for leading stocks in the sector were significant, with Zhongsheng Pharmaceutical showing a daily increase of 9.99% and a turnover rate of 3.84% [3][4] - Other stocks with notable performance included Fuxing Pharmaceutical with a 3.60% increase and a turnover rate of 2.17%, and Meinuo Pharmaceutical with a 9.97% increase and a turnover rate of 7.37% [3][4]

A股CRO概念板块震荡走强，睿智医药涨超17%，联化科技封板涨停，美诺华涨超9%，金凯生科、圣诺 生物、万邦医药、皓元医药等跟涨。 订阅A股市场资讯 +订阅 ...

Group 1 - The CRO concept sector has seen a significant rise, with companies like Lianhua Technology (002250) hitting the daily limit up, indicating strong investor interest [1] - Ruizhi Pharmaceutical (300149) has increased by over 10%, reflecting positive market sentiment towards the CRO sector [1] - Other companies such as Meinuohua (603538), Jinkai Biotechnology (301509), Shengnuo Biotech, Wanbang Pharmaceutical (301520), and Haoyuan Pharmaceutical have also experienced gains, showcasing a broader trend in the industry [1]

| | | 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 一、公司股票期权与限制性股票激励计划已进入行权期的股票期权情况： | 激励计划 | | 行权期 | | 行权代码 | | | | | 行权起止日期 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2021 公司 | 年股票期权与限制性 | | | | | | 2025 | 年 | 1 | 月 | 17 | 日至 | | 第三个行权期 | | | 0000000902 | | | | | | | | | | | 股票激励计划首次授予 | | | | | | | 2025 | 年 | 12 | 月 | 29 | 日 | | 公司 2021 | 年股票期权与限制性 | | | | | | 2024 | 年 | 12 | 月 | 25 | 日至 | | 第二个行权期 | | | 1000000274 | | | | | | | | | | | 股票激励计划预留授予 | | | | | | | 2025 | ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-070 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 董事会 2025 年 6 月 6 日 一、公司股票期权与限制性股票激励计划已进入行权期的股票期权情况： 二、本次限制行权期为：2025 年 6 月 11 日至 2025 年 6 月 26 日，上述期间 内全部激励对象将限制行权。 三、本公司将按照有关规定及时向中国证券登记结算有限责任公司上海分公 司申请办理限制行权相关事宜。 特此公告。 宁波美诺华药业股份有限公司 关于股票期权与限制性股票激励计划限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 因宁波美诺华药业股份有限公司（以下简称"公司"）计划开展 2024 年度权 益分派工作，根据《上市公司股权激励管理办法》《宁波美诺华药业股份有限公 司 2021 年股票期权与限制性股票激励计划（草案）》及中国证券登记结算有限责 任公司上海分公司关于股票 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-068 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于公司 2024 年限制性股票激励计划 预留限制性股票授予结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 宁波美诺华药业股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日在 中国证券登记结算有限责任公司上海分公司完成办理公司 2024 年限制性股票激 励计划（以下简称"激励计划"）预留限制性股票授予登记工作，现将具体情况 公告如下： 一、预留限制性股票授予情况 2、2025 年 4 月 17 日，公司召开第五届监事会第十三次会议，审议通过了 《关于 2024 年限制性股票激励计划预留部分授予的议案》。监事会对上述事项发 1 预留限制性股票授予登记日：2025 年 5 月 28 日 预留限制性股票授予登记数量：1,219,000 股 表了同意的核查意见。具体内容详见公司于 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-069 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于授予限制性股票增发股份调整可转债转股价格 暨转股停复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因宁波美诺华药业股份有限公司(以下简称"公司")本次限制性股票归属完成登 记增发新股，引发"美诺转债"转股价格调整,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | | | | 113618 | 美诺转债 | 可转债转股停牌 | 2025/5/30 | 全天 | 2025/5/30 | 2025/6/3 | "美诺转债"调整前转股价格：25.84 元/股 "美诺转债" ...

Core Viewpoint - The recent revision of the "Regulations on the Supervision of Fundraising by Listed Companies" by the China Securities Regulatory Commission emphasizes the need for dedicated use of raised funds, focusing on core business operations and supporting the development of the real economy. This regulation will take effect on June 15, 2025, and aims to enhance the safety and standardization of the use of raised funds [2][17]. Group 1: Fundraising and Project Changes - Meinuo Pharma has faced issues with slow progress in the use of raised funds, multiple changes to fundraising projects, and lower-than-expected project returns since its IPO in April 2017, which raised 381 million yuan [3][4]. - The company initially planned to invest 281 million yuan in a project to produce 3 billion solid dosage forms annually, but the completion date has been postponed multiple times, with the project only reaching usable status in December 2022 after an investment of 82.78 million yuan, significantly less than the planned amount [5][6]. - The expected internal rate of return for the solid dosage project was 25.72%, with a projected net profit of 143 million yuan, but actual returns in 2023 and 2024 were -5.54 million yuan and -10.20 million yuan, respectively [6][7]. Group 2: Additional Project Issues - The project for the production of 400 tons of raw materials also faced delays, with the completion date pushed to October 2022, and the actual returns in 2023 and 2024 were only 775,640 yuan and 3,965,840 yuan, far below the projected annual profit of 16.38 million yuan [7][8]. - The drug research center project was ultimately canceled after multiple delays, with no funds invested in it, as the company opted to acquire a related entity instead [8][9]. Group 3: Convertible Bond Fundraising - In January 2021, Meinuo Pharma issued convertible bonds totaling 520 million yuan, with plans to invest 400 million yuan in a high-end formulation project and 120 million yuan in working capital. However, this project has also faced delays, with completion now pushed to July 2025 [10][11]. - As of December 31, 2024, the company had invested 263 million yuan in the high-end formulation project, which is 67% of the promised investment [11][12]. Group 4: Regulatory Implications - The new regulations will impose stricter oversight on the use of raised funds, requiring companies to provide detailed explanations for any changes in project funding and to adhere to stricter disclosure requirements [17]. - Meinuo Pharma's past practices of changing project uses and delaying implementations may face increased scrutiny under the new rules, necessitating more careful planning and justification for any future changes [17].

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-067 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于"美诺转债"可选择回售结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次可转债回售的公告情况 宁波美诺华药业股份有限公司（以下简称"公司"）于 2025 年 5 月 9 日披 露了《宁波美诺华药业股份有限公司关于"美诺转债"可选择回售的公告》（公 告编号：2025-059），并分别于 2025 年 5 月 10 日、2025 年 5 月 13 日、2025 年 5 月 20 日披露了关于"美诺转债"可选择回售的提示性公告（公告编号分别为： 2025-060、2025-061、2025-065）。具体内容详见公司在上海证券交易所网站 （http://www.sse.com.cn/）等指定媒体披露的相关公告。 1 本次可选择回售的"美诺转债"的转债代码为"113618"，回售价格为 ...